로딩 중…
지수 로딩 중…
Evolus, Inc.
EOLS· NASDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
$7.16-2.59%
2026-11-02
Financials
Valuation Metrics
Evolus, Inc.'s Market Cap is $472M. At end of 2025 it was $429M. Ranked #2752 of 3,116 in US market (top 88%), #1204 of 1,472 on NASDAQ (top 82%), #219 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 83%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $472M | US#2,752/3,116 Sec#219/265 |
| Revenue | $316M | US#2,406/3,116 Sec#93/265 |
| Net Income | $-34M | US—/3,116 Sec—/265 |
| Total Assets | $248M | US#2,944/3,116 Sec#229/265 |
| Net Assets | $-31M | US#2,931/3,116 Sec#244/265 |
| Employees | 350 | US#2,373/3,116 Sec#105/265 |
| Value | ||
| P/S | 1.49x | US#1,054/3,116 Sec#19/265 |
| FCF Yield | -4.28% | US—/3,116 Sec—/265 |
| Profitability | ||
| ROA | -13.84% | US#2,719/3,116 Sec#115/265 |
| Op. Margin | -7.33% | US#2,492/3,116 Sec#92/265 |
| Revenue Growth | 13.87% | US#969/3,116 Sec#83/265 |
| Financial Health | ||
| Total Debt | $165M | US#2,297/3,116 Sec#101/265 |
| FCF | $-20M | US#2,419/3,116 Sec#95/265 |
| Cash | $45M | US#2,608/3,116 Sec#230/265 |
| Current Ratio | 1.70x | US#1,460/3,116 Sec#231/265 |
| Performance | ||
| 1Y Return | 10.84% | US#1,512/3,116 Sec#130/265 |
| 1M Return | 0.28% | US#2,347/3,116 Sec#171/265 |
| From 52W High | -23.09% | US#1,495/3,116 Sec#86/265 |
| 1Y MDD | -46.54% | US#2,248/3,116 Sec#147/265 |
| Trading | ||
| Volume | 564,333 shares | US#1,716/3,116 Sec#175/265 |
| Trading Value | $4M | US#2,580/3,116 Sec#209/265 |
| Per Share | ||
| EPS | $-0.52 | US—/3,116 Sec—/265 |
| BPS | $-0.47 | US—/3,116 Sec—/265 |
Company Info
Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.